Share-based Payment Arrangement, Expense of Design Therapeutics, Inc. from 31 Mar 2020 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Design Therapeutics, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Mar 2020 to 30 Sep 2025.
  • Design Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $3,590,000, a 15% increase year-over-year.
  • Design Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $14,585,000, a 18% increase year-over-year.
  • Design Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $13,072,000, a 0.12% decline from 2023.
  • Design Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $13,088,000, a 20% increase from 2022.
  • Design Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $10,925,000, a 133% increase from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Design Therapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $14,585,000 $3,590,000 +$472,000 +15% 01 Jul 2025 30 Sep 2025 10-Q 05 Nov 2025 2025 Q3
Q2 2025 $14,113,000 $3,985,000 +$686,000 +21% 01 Apr 2025 30 Jun 2025 10-Q 07 Aug 2025 2025 Q2
Q1 2025 $13,427,000 $3,539,000 +$355,000 +11% 01 Jan 2025 31 Mar 2025 10-Q 07 May 2025 2025 Q1
Q4 2024 $13,072,000 $3,471,000 +$747,000 +27% 01 Oct 2024 31 Dec 2024 10-K 10 Mar 2025 2024 FY
Q3 2024 $12,325,000 $3,118,000 -$101,000 -3.1% 01 Jul 2024 30 Sep 2024 10-Q 05 Nov 2025 2025 Q3
Q2 2024 $12,426,000 $3,299,000 -$420,000 -11% 01 Apr 2024 30 Jun 2024 10-Q 07 Aug 2025 2025 Q2
Q1 2024 $12,846,000 $3,184,000 -$242,000 -7.1% 01 Jan 2024 31 Mar 2024 10-Q 07 May 2025 2025 Q1
Q4 2023 $13,088,000 $2,724,000 -$352,000 -11% 01 Oct 2023 31 Dec 2023 10-K 10 Mar 2025 2024 FY
Q3 2023 $13,440,000 $3,219,000 +$347,000 +12% 01 Jul 2023 30 Sep 2023 10-Q 07 Nov 2024 2024 Q3
Q2 2023 $13,093,000 $3,719,000 +$1,102,000 +42% 01 Apr 2023 30 Jun 2023 10-Q 05 Aug 2024 2024 Q2
Q1 2023 $11,991,000 $3,426,000 +$1,066,000 +45% 01 Jan 2023 31 Mar 2023 10-Q 08 May 2024 2024 Q1
Q4 2022 $10,925,000 $3,076,000 +$1,520,000 +98% 01 Oct 2022 31 Dec 2022 10-K 19 Mar 2024 2023 FY
Q3 2022 $9,405,000 $2,872,000 +$1,629,000 +131% 01 Jul 2022 30 Sep 2022 10-Q 13 Nov 2023 2023 Q3
Q2 2022 $7,776,000 $2,617,000 +$1,374,000 +111% 01 Apr 2022 30 Jun 2022 10-Q 14 Aug 2023 2023 Q2
Q1 2022 $6,402,000 $2,360,000 +$1,713,000 +265% 01 Jan 2022 31 Mar 2022 10-Q 09 May 2023 2023 Q1
Q4 2021 $4,689,000 $1,556,000 +$1,135,000 +270% 01 Oct 2021 31 Dec 2021 10-K 14 Mar 2023 2022 FY
Q3 2021 $3,554,000 $1,243,000 +$1,228,000 +8187% 01 Jul 2021 30 Sep 2021 10-Q 03 Nov 2022 2022 Q3
Q2 2021 $2,326,000 $1,243,000 +$1,233,000 +12330% 01 Apr 2021 30 Jun 2021 10-Q 08 Aug 2022 2022 Q2
Q1 2021 $1,093,000 $647,000 +$643,000 01 Jan 2021 31 Mar 2021 10-Q 09 May 2022 2022 Q1
Q4 2020 $450,000 $421,000 01 Oct 2020 31 Dec 2020 10-K 10 Mar 2022 2021 FY
Q3 2020 $15,000 01 Jul 2020 30 Sep 2020 10-Q 09 Nov 2021 2021 Q3
Q2 2020 $10,000 01 Apr 2020 30 Jun 2020 10-Q 09 Aug 2021 2021 Q2
Q1 2020 $4,000* 01 Jan 2020 31 Mar 2020 10-Q 10 May 2021 2021 Q1

Design Therapeutics, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $13,072,000 -$16,000 -0.12% 01 Jan 2024 31 Dec 2024 10-K 10 Mar 2025 2024 FY
2023 $13,088,000 +$2,163,000 +20% 01 Jan 2023 31 Dec 2023 10-K 10 Mar 2025 2024 FY
2022 $10,925,000 +$6,236,000 +133% 01 Jan 2022 31 Dec 2022 10-K 19 Mar 2024 2023 FY
2021 $4,689,000 +$4,239,000 +942% 01 Jan 2021 31 Dec 2021 10-K 14 Mar 2023 2022 FY
2020 $450,000 01 Jan 2020 31 Dec 2020 10-K 10 Mar 2022 2021 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.